Intuitive Surgical, Inc. $ISRG Shares Sold by Bowen Hanes & Co. Inc.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Bowen Hanes & Co. Inc. trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 0.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 184,315 shares of the medical equipment provider's stock after selling 615 shares during the quarter. Intuitive Surgical comprises 2.5% of Bowen Hanes & Co. Inc.'s portfolio, making the stock its 7th biggest holding. Bowen Hanes & Co. Inc. owned 0.05% of Intuitive Surgical worth $91,286,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. AlphaCore Capital LLC increased its position in Intuitive Surgical by 4.2% during the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after buying an additional 18 shares during the last quarter. Second Line Capital LLC increased its position in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after buying an additional 19 shares during the last quarter. Colonial Trust Co SC increased its position in Intuitive Surgical by 8.8% during the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock worth $128,000 after buying an additional 20 shares during the last quarter. Crown Wealth Group LLC increased its position in Intuitive Surgical by 4.8% during the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after buying an additional 20 shares during the last quarter. Finally, FSM Wealth Advisors LLC increased its position in Intuitive Surgical by 3.8% during the first quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider's stock worth $270,000 after buying an additional 20 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 4,500 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the sale, the senior vice president owned 907 shares of the company's stock, valued at approximately $510,740.77. The trade was a 19.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,839 shares of company stock worth $7,896,972. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded up $6.28 during mid-day trading on Friday, hitting $476.16. The company had a trading volume of 2,023,902 shares, compared to its average volume of 1,973,062. The business's 50-day simple moving average is $504.42 and its 200-day simple moving average is $522.06. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The firm has a market cap of $170.69 billion, a P/E ratio of 66.41, a PEG ratio of 4.92 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same quarter last year, the company earned $1.78 earnings per share. The firm's revenue was up 21.4% on a year-over-year basis. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on ISRG shares. Royal Bank Of Canada reissued an "outperform" rating and set a $615.00 target price on shares of Intuitive Surgical in a research report on Tuesday. Evercore ISI upped their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Piper Sandler restated an "overweight" rating and set a $595.00 price target (up from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. BTIG Research upped their price target on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, UBS Group upped their price target on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Thirteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.